Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential

European Journal of Heart Failure

Volumn 17, Issue 8, 2015, Pages 764-771

  Heymans, Stephane ^a   González, Arantxa ^b,c   Pizard, Anne ^d   Papageorgiou, Anna P ^a   Lõpez Andrés, Natalia ^c,e   Jaisser, Frédéric ^f   Thum, Thomas ^g   Zannad, Faiez ^d   Díez, Javier ^b,c,h  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF NAVARRA   (Spain)

^c Recinto de Complejo Hospitalario de Navarra   (Spain)

^d UNIVERSITÉ DE LORRAINE   (France)

^e Atención Primaria Y Promoción de La Salud   (Spain)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Heart failure; Interstitial fibrosis; Therapeutic targets

Indexed keywords

BIOLOGICAL MARKER; CARDIOTROPHIN 1; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GALECTIN 3; MATRIX PROTEIN; MESSENGER RNA; MIMECAN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEONECTIN; PROTEIN LYSINE 6 OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; CCN PROTEIN; CYTOKINE; MICRORNA;

CELL DIFFERENTIATION; COLLAGEN DEPOSITION; COLLAGEN METABOLISM; COLLAGEN SYNTHESIS; DIAGNOSTIC VALUE; HEART FIBROBLAST; HEART MUSCLE FIBROSIS; HUMAN; MOLECULAR PATHOLOGY; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REVIEW; ANIMAL; CARDIAC MUSCLE; FIBROBLAST; FIBROSIS; GENE EXPRESSION; GENETICS; HEART FAILURE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CCN INTERCELLULAR SIGNALING PROTEINS; COLLAGEN; CYTOKINES; FIBROBLASTS; FIBROSIS; GALECTIN 3; GENE EXPRESSION; HEART FAILURE; HUMANS; MICRORNAS; MYOCARDIUM; NADPH OXIDASE; PROTEIN-LYSINE 6-OXIDASE;

EID: 84938556009     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.312     Document Type: Review

References (68)

1. Weber KT, Pick R, Jalil JE, Janicki JS, Carroll EP,. Patterns of myocardial fibrosis. J Mol Cell Cardiol 1989; 21 Suppl 5: 121-131.
2. Weber KT,. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989; 13: 1637-1652.
3. Kong P, Christia P, Frangogiannis NG,. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 2014; 71: 549-574.
4. Segura AM, Frazier OH, Buja LM,. Fibrosis and heart failure. Heart Fail Rev 2014; 19: 173-185.
5. Querejeta R, Lõpez B, González A, Sánchez E, Larman M, Martínez Ubago JL, Díez J,. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004; 110: 1263-1268.
6. Aoki T1, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, Nakayama M, Shimokawa H,. Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. Comparison between preserved and reduced ejection fraction heart failure. Circ J 2011; 75: 2605-2613.
7. Yamada T, Fukunami M, Ohmori M, Iwakura K, Kumagai K, Kondoh N, Minamino T, Tsujimura E, Nagareda T, Kotoh K,. Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint. J Am Coll Cardiol 1993; 21: 628-633.
8. Jougasaki M., Cardiotrophin-1 in cardiovascular regulation. Adv Clin Chem 2012; 52: 41-76.
9. Drobic V, Cunnington RH, Bedosky KM, Raizman JE, Elimban VV, Rattan SG, Dixon IM,. Differential and combined effects of cardiotrophin-1 and TGF-beta1 on cardiac myofibroblast proliferation and contraction. Am J Physiol Heart Circ Physiol 2007; 293: H1053-H1064.
10. Lõpez B, González A, Querejeta R, Larman M, Rábago G, Díez J,. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension 2014; 63: 483-489.
11. Lõpez-Andrés N, Rousseau A, Akhtar R, Calvier L, Iñigo C, Labat C, Zhao X, Cruickshank K, Díez J, Zannad F, Lacolley P, Rossignol P,. Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. Hypertension 2012; 60: 563-573.
12. Lõpez-Andrés N, Martín-Fernández B, Rossignol P, Zannad F, Lahera V, Fortuño MA, Cachofeiro V, Díez J,. A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. Am J Physiol Heart Circ Physiol 2011; 301: H2372-H2382.
13. Lõpez-Andrés N, Calvier L, Labat C, Fay R, Díez J, Benetos A, Zannad F, Lacolley P, Rossignol P,. Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension 2013; 61: 120-129.
14. Zolk O, Ng LL, O'Brien RJ, Weyand M, Eschenhagen T,. Augmented expression of cardiotrophin-1 in failing human hearts is accompanied by diminished glycoprotein 130 receptor protein abundance. Circulation 2002; 106: 1442-1446.
15. Lõpez B, González A, Lasarte JJ, Sarobe P, Borrás F, Díaz A, Barba J, Tomás L, Lozano E, Serrano M, Varo N, Beloqui O, Díez J,. Is plasma cardiotrophin-1 a marker of hypertensive heart disease ? J Hypertens 2005; 23: 625-632.
16. Ochieng J, Furtak V, Lukyanov P,. Extracellular functions of galectin-3. Glycoconj J 2004; 19: 527-535.
17. Kim H, Lee J, Hyun JW, Park JW, Joo H, Shin T,. Expression of galectin-3 in various mouse tissues. Cell Biol Int 2007; 31: 655-662.
18. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, Lõpez-Andrés N,. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013; 33: 67-75.
19. Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, Greaves DR,. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008; 28: 433-440.
20. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B, André S, Crijns HJGM, Gabius H-J, Maessen J, Pinto YM,. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004; 110: 3121-3131.
21. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein IJ, Koerts JA, van Veldhuisen DJ, Bank RA, van Gilst WH, Silljé HH, de Boer RA,. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013; 6: 107-117.
22. Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, Zannad F, Rossignol P, Lõpez-Andrés N,. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail 2015; 3: 59-67.
23. Lõpez-Andrés N, Rossignol P, Iraqi W, Fay R, Nuée J, Ghio S, Cleland JGF, Zannad F, Lacolley P,. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012; 14: 74-81.
24. Blanchard H, Yu X, Collins PM, Bum-Erdene K,. Galectin-3 inhibitors: a patent review (2008-present). Expert Opin Ther Pat 2014; 24: 1053-1065.
25. Miguel-Carrasco JL, Baltanás A, Cebrián C, Moreno MU, Lõpez B, Hermida N, González A, Dotor J, Borrás-Cuesta F, Díez J, Fortuño A, Zalba G,. Blockade of TGF-β 1 signalling inhibits cardiac NADPH oxidase overactivity in hypertensive rats. Oxid Med Cell Longev 2012; 2012: 726940.
26. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM,. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 2006; 20: 1546-1548.
27. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D,. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005; 97: 900-907.
28. Murdoch CE, Chaubey S, Zeng L, Yu B, Ivetic A, Walker SJ, Vanhoutte D, Heymans S, Grieve DJ, Cave AC, Brewer AC, Zhang M, Shah AM,. Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition. J Am Coll Cardiol 2014; 63: 2734-2741.
29. Gandhi MS, Kamalov G, Shahbaz AU, Bhattacharya SK, Ahokas RA, Sun Y, Gerling IC, Weber KT,. Cellular and molecular pathways to myocardial necrosis and replacement fibrosis. Heart Fail Res 2011; 16: 23-34.
30. Lijnen PJ, van Pelt JF, Fagard RH,. Stimulation of reactive oxygen species and collagen synthesis by angiotensin II in cardiac fibroblasts. Cardiovasc Ther 2012; 30: e1-8.
31. Ma Y, Li H, Yue Z, Guo J, Xu S, Xu J, Jia Y, Yu N, Zhang B, Liu S, Liu M, Shao W, Chen S, Liu P,. Cryptotanshinone attenuates cardiac fibrosis via downregulation of COX-2, NOX-2, and NOX-4. J Cardiovasc Pharmacol 2014; 64: 28-37.
32. Latouche C, El Moghrabi S, Messaoudi S, Cat AN, Hernandez-Diaz I, Alvarez de laRosa D, Perret C, Lopez-Andrés N, Rossignol P, Zannad F, Farman N, Jaisser F., Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. Hypertension 2012; 59: 966-972.
33. Yndestad A, Landrø L, Ueland T, Dahl CP, Flo TH, Vinge LE, Espevik T, Frøland SS, Husberg C, Christensen G, Dickstein K, Kjekshus J, Øie E, Gullestad L, Aukrust P,. Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J 2009; 30: 1229-1236.
34. Yan L, Borregaard N, Kjeldsen L, Moses MA,. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001; 276: 37258-37265.
35. Ding L, Hanawa H, Ota Y, Hasegawa G, Hao K, Asami F, Watanabe R, Yoshida T, Toba K, Yoshida K, Ogura M, Kodama M, Aizawa Y,. Lipocalin-2/neutrophil gelatinase-B associated lipocalin is strongly induced in hearts of rats with autoimmune myocarditis and in human myocarditis. Circ J 2010; 74: 523-530.
36. Villar AV, Garcia R, Merino D, Llano M, Cobo M, Montalvo C, Martín-Durán R, Hurlé MA, Nistal JF,. Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients. Int J Cardiol 2013; 167: 2875-2881.
37. Montgomery RL, Hullinger TG, Semus HM, Stack C, Latimer PA, Lewton SM, Lynch JM, Hullinger TG, Seto AG, van Rooij E,. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011; 124: 1537-1547.
38. Shieh JT, Huang Y, Gilmore J, Srivastava D,. Elevated miR-499 levels blunt the cardiac stress response. PLoS One 2011; 6:e19481.
39. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN,. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105: 13027-13032.
40. van Almen GC, Verhesen W, van Leeuwen RE, van de Vrie M, Eurlings C, Schellings MW, Swinnen M, Cleutjens JP, van Zandvoort MA, Heymans S, Schroen B,. MicroRNA-18 and -19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell 2011; 10: 769-779.
41. Karakikes I, Chaanine AH, Kang S, Mukete BN, Jeong D, Zhang S, Hajjar RJ, Lebeche D,. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc 2013; 2:e000078.
42. Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G, Diwan A, Nerbonne JM, Dorn GW 2nd,. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 2009; 106: 166-175.
43. Beaumont J, Lopez B, Hermida N, Schroen B, San José G, Heymans S, Valencia F, Gõmez-Doblas JJ, De Teresa E, Díez J, González A,. MicroRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-beta1 up-regulation. Clin Sci (Lond) 2014; 126: 497-506.
44. Dawson K, Wakili R, Ordog B, Clauss S, Chen Y, Iwasaki Y, Voigt N, Qi XY, Sinner MF, Dobrev D, Kääb S, Nattel S,. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation 2013; 127: 1466-1475.
45. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, Wagner DR, Staessen JA, Heymans S, Schroen B,. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 2010: 3: 499-506.
46. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S,. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456: 980-984.
47. Kumarswamy R, Volkmann I, Jazbutyte V, Dangwal S, Park DH, Thum T,. Transforming growth factor-β-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Arterioscler Thromb Vasc Biol 2012; 32: 361-369.
48. Abonnenc M, Nabeebaccus AA, Mayr U, Barallobre-Barreiro J, Dong X, Cuello F, Sur S, Drozdov I, Langley SR, Lu R, Stathopoulou K, Didangelos A, Yin X, Zimmermann WH, Shah AM, Zampetaki A, Mayr M,. Extracellular matrix secretion by cardiac fibroblasts: role of microRNA-29b and microRNA-30c. Circ Res 2013; 113: 1138-1147.
49. Wang J, Huang W, Xu R, Nie Y, Cao X, Meng J, Xu X, Hu S, Zheng Z,. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med 2012; 16: 2150-2160.
50. Pan Z, Sun X, Shan H, Wang N, Wang J, Ren J, Feng S, Xie L, Lu C, Yuan Y, Zhang Y, Wang Y, Lu Y, Yang B,. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the PBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 2012; 126: 840-850.
51. Dakhlallah D, Zhang J, Yu L, Marsh CB, Angelos MG, Khan M,. MicroRNA-133a engineered mesenchymal stem cells augment cardiac function and cel survival in the infarct heart. J Cardiovasc Pharmacol 2015; 65: 241-251.
52. Maurer P, Gohring W, Sasaki T, Mann K, Timpl R, Nischt R,. Recombinant and tissue-derived mouse BM-40 bind to several collagen types and have increased affinities after proteolytic activation. Cell Mol Life Sci 1997; 53: 478-484.
53. Chen W, Frangogiannis NG,. The role of inflammatory and fibrogenic pathways in heart failure associated with aging. Heart Fail Rev 2010; 15: 415-422.
54. Motamed K, Funk SE, Koyama H, Ross R, Raines EW, Sage EH,. Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors. J Cell Biochem 2002; 84: 759-771.
55. Francki A, McClure TD, Brekken RA, Motamed K, Murri C, Wang T, Sage EH,. Sparc regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem 2004; 91: 915-925.
56. Schellings MW, Vanhoutte D, Swinnen M, Cleutjens JP, Debets J, van Leeuwen RE, d'Hooge J, Van de Werf F, Carmeliet P, Pinto YM, Sage EH, Heymans S,. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med 2009; 206: 113-123.
57. Bradshaw AD, Baicu CF, Rentz TJ, Van Laer AO, Boggs J, Lacy JM, Zile MR,. Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. Circulation 2009; 119: 269-280.
58. Bradshaw AD, Baicu CF, Rentz TJ, Van Laer AO, Bonnema DD, Zile MR,. Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Am J Physiol Heart Circ Physiol 2010; 298: H614-H622.
59. Chen S, Birk DE,. The regulatory roles of small leucine-rich proteoglycans in extracellular matrix assembly. FEBS J 2013; 280: 2120-2137.
60. Petretto E, Sarwar R, Grieve I, Lu H, Kumaran MK, Muckett PJ, Mangion J, Schroen B, Benson M, Punjabi PP, Prasad SK, Pennell DJ, Kiesewetter C, Tasheva ES, Corpuz LM, Webb MD, Conrad GW, Kurtz TW, Kren V, Fischer J, Hubner N, Pinto YM, Pravenec M, Aitman TJ, Cook SA,. Integrated genomic approaches implicate osteoglycin (OGN) in the regulation of left ventricular mass. Nat Genet 2008; 40: 546-552.
61. Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Gaggin HK, Bhardwaj A, Januzzi JL Jr., Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling. J Cardiovasc Transl Res 2014; 7: 250-261.
62. Van Aelst LN, Voss S, Carai P, van Leeuwen R, Vanhoutte D, Sanders-van Wijk S, Eurlings L, Swinnen M, Verheyen FA, Verbeken EK, Nef H, Troidl C, Cook SA, Brunner-La Rocca HP, Möllmann H, Papageorgiou AP, Heymans S,. Osteoglycin prevents cardiac dilatation and dysfunction after myocardial infarction through infarct collagen strengthening. Circ Res 2014; 116: 425-436.
63. Hermida N, Lõpez B, González A, Dotor J, Lasarte JJ, Sarobe P, Borrás-Cuesta F, Díez J,. A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res 2009; 81: 601-609.
64. McCormick RJ, Musch TI, Bergman BC, Thomas DP,. Regional differences in LV collagen accumulation and mature cross-linking after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 1994; 266: H354-H359.
65. Zibadi S, Vazquez R, Moore D, Larson DF, Watson RR,. Myocardial lysyl oxidase regulation of cardiac remodeling in a murine model of diet-induced metabolic syndrome. Am J Physiol Heart Circ Physiol 2009; 297: H976-H982.
66. Lõpez B, Querejeta R, González A, Beaumont J, Larman M, Díez J,. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009; 53: 236-242.
67. Kasner M, Westermann D, Lõpez B, Gaub R, Escher F, Kühl U, Schultheiss HP, Tschöpe C,. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol 2011; 57: 977-985.
68. Lõpez B, Querejeta R, González A, Larman M, Díez J,. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. Hypertension 2012; 60: 677-683.